CA2396235A1 - Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation - Google Patents

Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation Download PDF

Info

Publication number
CA2396235A1
CA2396235A1 CA002396235A CA2396235A CA2396235A1 CA 2396235 A1 CA2396235 A1 CA 2396235A1 CA 002396235 A CA002396235 A CA 002396235A CA 2396235 A CA2396235 A CA 2396235A CA 2396235 A1 CA2396235 A1 CA 2396235A1
Authority
CA
Canada
Prior art keywords
tumstatin
integrin
cells
fragment
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002396235A
Other languages
English (en)
Inventor
Raghuram Kalluri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/625,191 external-priority patent/US6962974B1/en
Application filed by Individual filed Critical Individual
Publication of CA2396235A1 publication Critical patent/CA2396235A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des protéines et des fragments de celles-ci possédant des propriétés anti-angiogéniques, ainsi que des méthodes d'utilisation de ces protéines et de ces fragments permettant d'inhiber ou de promouvoir l'angiogénèse.
CA002396235A 2000-01-07 2001-01-08 Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation Abandoned CA2396235A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US47911800A 2000-01-07 2000-01-07
US09/479,118 2000-01-07
US54337100A 2000-04-04 2000-04-04
US09/543,371 2000-04-04
US09/625,191 US6962974B1 (en) 1998-06-17 2000-07-21 Anti-angiogenic proteins and fragments and methods of use thereof
US09/625,191 2000-07-21
PCT/US2001/000565 WO2001051523A2 (fr) 2000-01-07 2001-01-08 Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation

Publications (1)

Publication Number Publication Date
CA2396235A1 true CA2396235A1 (fr) 2001-07-19

Family

ID=27413473

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002396235A Abandoned CA2396235A1 (fr) 2000-01-07 2001-01-08 Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation

Country Status (6)

Country Link
EP (1) EP1337633A2 (fr)
JP (1) JP2003519630A (fr)
CN (1) CN1420926A (fr)
AU (2) AU783662B2 (fr)
CA (1) CA2396235A1 (fr)
WO (1) WO2001051523A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10106597B2 (en) 2010-12-10 2018-10-23 The Johns Hopkins University Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphangiogenesis-dependent diseases

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
EP1363653A4 (fr) * 2000-10-02 2004-12-22 Scripps Research Inst Procedes et compositions pour renforcer l'angiogenese
EP1573025A4 (fr) 2001-07-27 2006-07-19 Univ Kansas Medical Center Structure cristallisee de l'hexamere du domaine nc1 du collagene de type iv
WO2003093303A1 (fr) 2002-05-06 2003-11-13 Board Of Regents, The University Of Texas System Ciblage de proteines pour l'apport de reactifs therapeutiques ou de diagnostic
WO2004067762A2 (fr) * 2003-01-27 2004-08-12 University Of Kansas Medical Center Structure cristallisee hexamere a domaine nc1 de collagene de type iv
JP4843767B2 (ja) * 2005-08-31 2011-12-21 国立大学法人 岡山大学 がん細胞特異的遺伝子発現法を用いた血管新生阻害薬
WO2007087689A1 (fr) * 2006-02-03 2007-08-09 Crc For Asthma And Airways Ltd Procede de modulation de l'activite cellulaire et agents a utiliser dans le cadre de celui-ci
FR2898895B1 (fr) * 2006-03-23 2012-04-06 Univ Reims Champagne Ardenne Cyclopeptide a activite anti-cancereuse derive du collagene de type iv
CN102145161A (zh) * 2011-04-07 2011-08-10 中国药科大学 整合素阻断剂在制备治疗肿瘤药物中的应用
GB201721387D0 (en) * 2017-12-20 2018-01-31 Nordic Bioscience As Tumstatin assay
CN113735966B (zh) * 2021-09-29 2022-11-01 陕西巨子生物技术有限公司 一种抗肿瘤重组胶原蛋白及其制备方法和应用
CN114931665A (zh) * 2021-12-14 2022-08-23 广州医科大学 六型胶原α2亚基在神经修复产品中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU748751B2 (en) * 1998-03-27 2002-06-13 University Of Kansas Medical Center The use of isolated domains of type IV collagen to modify cell and tissue interactions
IL140239A0 (en) * 1998-06-17 2002-02-10 Beth Israel Hospital Anti-angiogenic proteins and methods of use thereof
WO2000059532A1 (fr) * 1999-04-01 2000-10-12 Biostratum, Inc. Utilisation de domaine de collagene de type iv permettant d'inhiber l'angiogenese et la croissance tumorale

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10106597B2 (en) 2010-12-10 2018-10-23 The Johns Hopkins University Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphangiogenesis-dependent diseases
US10774131B2 (en) 2010-12-10 2020-09-15 The Johns Hopkins University Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphangiogenesis-dependent diseases
US11155603B2 (en) 2010-12-10 2021-10-26 The Johns Hopkins University Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases

Also Published As

Publication number Publication date
CN1420926A (zh) 2003-05-28
WO2001051523A2 (fr) 2001-07-19
EP1337633A2 (fr) 2003-08-27
AU2635601A (en) 2001-07-24
WO2001051523A3 (fr) 2002-08-08
JP2003519630A (ja) 2003-06-24
AU783662B2 (en) 2005-11-24
AU2006200751A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
US7387779B2 (en) Anti-angiogenic proteins and fragments and methods of use thereof
AU2006200751A1 (en) Anti-Angiogenic Proteins and Fragments and Methods of Use Thereof
AU753249B2 (en) Anti-angiogenic proteins and methods of use thereof
CA2313251A1 (fr) Mutants d'endostatine "em 1" presentant une activite anti-angiogenique et leurs methodes d'utilisation
US6962974B1 (en) Anti-angiogenic proteins and fragments and methods of use thereof
US6759047B1 (en) Anti-angiogenic proteins and methods of use thereof
US20050255107A1 (en) Anti-angiogenic proteins and fragments and methods of use thereof
US20080167227A1 (en) Anti-angiogenic and anti-tumor properties of matin and other laminin domains
US6852691B1 (en) Anti-angiogenic peptides and methods of use thereof
AU2001245994B2 (en) Anti-angiogenic and anti-tumor properties of matin and other laminin domains
CA2403515A1 (fr) Proprietes anti-angiogenes et anti-tumorales de la vascostatine et d'autres domaines nidogenes
AU2001287274B2 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
EP1719779A2 (fr) Anticorps contre le Matin
US20080167232A1 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other indogen domains
AU2001245994A1 (en) Anti-angiogenic and anti-tumor properties of matin and other laminin domains
AU2001287274A1 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead